Gapping up
In reaction to strong earnings/guidance: ASTI +97.2%, RYAAY +5.6%, BT +2.5%, CNP +2.1%, CAH +1.4%, AET+1.1%, DM +1%
M&A news: ALR +46.1% (Alere to be acquired by Abbott (ABT) for $56/share, or ~$5.8 bln), AYA +23.1% (Chairman and CEO announces intention to make an all-cash proposal to acquire Amaya for CDN 21.00/share (shares halted) vs. CDN 14.99 close in Toronto on Friday), STR +20.2% (Dominion (D) has agreed to pay Questar shareholders $25 per share -- about $4.4 bln -- and assume Questar's outstanding debt), AAVL +4% (acquires Annapurna Therapeutics, all stock transaction), MAT+1.5% (acquires Fuhu and Sproutling; terms not disclosed), ABT +0.5%
Other news: MSTX +12.8% (reports 'positive' top-line results from a blinded Phase 2a study of AIR001), TWTR +6.5% (strength attributed to article from The Information; discusses deal possibilities, potential interest from Marc Andreessen and Silver Lake), ACAD +5.8% (confirms March 29 FDA advisory committee meeting to review nuplazid (pimavanserin) for treatment of Parkinson's disease; PDUFA May 1), INO +5.4% (cont strength), CMG +4.6% (The CDC is expected to announce that Chipotle's E. coli outbreak is over, thus closing its investigation, according to the WSJ; also upgraded to Neutral from Underperform at BofA/Merrill), EXEL +2.8% (positive overall survival results from meteor), AGI +2.2% (cont strength), HLF+2.2% (still checking), CNHI +0.8% (to launch common shares buyback program of $300 mln; also upgraded to Neutral from Underperform at BofA/Merrill)
Analyst comments: SDPI +4.9% (upgraded to Buy at Wunderlich), JOY +2.8% (upgraded to Overweight from Equal Weight at Barclays)
In reaction to strong earnings/guidance: ASTI +97.2%, RYAAY +5.6%, BT +2.5%, CNP +2.1%, CAH +1.4%, AET+1.1%, DM +1%
M&A news: ALR +46.1% (Alere to be acquired by Abbott (ABT) for $56/share, or ~$5.8 bln), AYA +23.1% (Chairman and CEO announces intention to make an all-cash proposal to acquire Amaya for CDN 21.00/share (shares halted) vs. CDN 14.99 close in Toronto on Friday), STR +20.2% (Dominion (D) has agreed to pay Questar shareholders $25 per share -- about $4.4 bln -- and assume Questar's outstanding debt), AAVL +4% (acquires Annapurna Therapeutics, all stock transaction), MAT+1.5% (acquires Fuhu and Sproutling; terms not disclosed), ABT +0.5%
Other news: MSTX +12.8% (reports 'positive' top-line results from a blinded Phase 2a study of AIR001), TWTR +6.5% (strength attributed to article from The Information; discusses deal possibilities, potential interest from Marc Andreessen and Silver Lake), ACAD +5.8% (confirms March 29 FDA advisory committee meeting to review nuplazid (pimavanserin) for treatment of Parkinson's disease; PDUFA May 1), INO +5.4% (cont strength), CMG +4.6% (The CDC is expected to announce that Chipotle's E. coli outbreak is over, thus closing its investigation, according to the WSJ; also upgraded to Neutral from Underperform at BofA/Merrill), EXEL +2.8% (positive overall survival results from meteor), AGI +2.2% (cont strength), HLF+2.2% (still checking), CNHI +0.8% (to launch common shares buyback program of $300 mln; also upgraded to Neutral from Underperform at BofA/Merrill)
Analyst comments: SDPI +4.9% (upgraded to Buy at Wunderlich), JOY +2.8% (upgraded to Overweight from Equal Weight at Barclays)